丹红注射液联合泼尼松龙用于特发性肺纤维化患者的临床治疗效果

目的:探究特发性肺纤维化患者应用丹红注射液联合泼尼松龙治疗的临床疗效.方法:选择本院2018年4月至2020年10月收治的82例特发性肺纤维化患者为研究对象,按照随机表法分成两组,其中41例使用泼尼松龙治疗的患者为对照组,另外41例使用丹红注射液联合泼尼松龙治疗的患者为实验组,分析两种不同方案的疗效.结果:治疗前,实验...     

特发性肺纤维化44例治疗分析

目的 探讨特发性肺纤维化的有效治疗方法.方法 采用布地奈德混悬液雾化吸入联合静脉输注丹红注射液对44例特发性肺纤维化患者进行治疗观察.结果 本组44例患者治疗后,反应良好或改善37例,反应差或治疗失败7例,总有效率84.1%.治疗过程中均未出现明显不良反应,全部顺利完成治疗.结论 布地奈德混悬液雾化吸入联合静脉输注丹红注射液具有临床效果满意,无明显不良反应,患者依从性好等特点,是治疗特发性肺纤维化的有效方法.     

布地奈德混悬液雾化吸入联合静脉滴注黄芪注射液治疗特发性肺纤维化的临床观察

目的探讨布地奈德混悬液雾化吸人联合静脉滴注黄芪注射液治疗特发性肺纤维化的临床疗效。方法将46例特发性肺纤维化患者随机分为观察组和对照组各23例，对照组采用布地奈德混悬液雾化吸入；观察组在对照组治疗方法的基础上加用黄芪注射液静脉滴注。结果治疗3个月后，对照组反应良好或改善15例，反应差或治疗失败8例，有效率65．22％。观察组反应良好或改善20例，反应差或治疗失败3例，有效率86．96％。经统计学处理，两组的有效率相比较，差异具有统计学意义（P〈0．05）。治疗过程中两组均未出现明显不良反应。结论采用布地奈德混悬液雾化吸入联合静脉滴注黄芪注射液来治疗特发性肺纤维化的临床疗效显著，患者依从性好，未见明显不良反应，值得进一步研究和应用。     

多药联合治疗特发性肺纤维化50例

目的观察丹红注射液合泼尼松、替米沙坦治疗特发性肺纤维化的临床疗效。方法选取101例特发性肺纤维化患者,随机分为两组,对照组51例,予泼尼松0.5mg/（kg·d）,分次口服,连用4周,后减为0.25mg/（kg·d）,并予替米沙坦40mg/d,口服。治疗组50例,在对照组的基础上给予丹红注射液30ml加入生理盐水250ml中静脉滴注,1次/d。疗程均为8周。结果丹红注射液合泼尼松、替米沙坦治疗疗效明显优于对照组,差异有统计学意义（P〈0.05）。结论丹红注射液合泼尼松、替米沙坦治疗特发性肺纤维化疗效确切。     

丹红注射液治疗脑梗死的疗效观察

目的观察丹红注射液治疗脑梗死的临床疗效。方法73例脑梗死患者分为对照组和治疗组,两组给予相同的基础治疗,治疗组用丹红注射液,对照组给予脉络宁注射液,疗程2周,观察治疗前后血流变学变化及疗效。结果丹红注射液治疗脑梗死,总有效率89．18％,明显高于对照组;同时对全血粘度、血浆粘度、红细胞压积的改善作用尤为显著。结论丹红注射液治疗脑梗死效果优于脉络宁,副反应少,值得推广应用。     

丹红注射液治疗脑梗死临床疗效观察

目的观察丹红注射液治疗脑梗死的临床疗效。方法160例经临床和头CT扫描确认为脑梗死的患者，随机分为丹红治疗组和血塞通注射液对照组，两组应用其他常规治疗药物相同。两组均于治疗一个疗程后详查症状及体征等进行疗效评定。结果治疗组总有效率为93．75％，明显优于对照组86．25％，P〈0．05。结论丹红注射液能有效改善脑部血液循环，增加脑血流量，促进侧支循环的建立与开放，恢复梗死区，尤其是梗死周边缺血半暗区脑细胞的功能，并在预防脑心综合征上起到极为重要的作用。     

丹红注射液治疗冠心病的临床疗效观察

目的观察丹红注射液治疗冠心病的效果。方法我科2012年1月至2013年1月住院268例冠心病患者,将患者随机分为两组,患者在治疗前后分别留取常规心电图、测定血液流变学参数,记录心绞痛发作次数。结果治疗组患者心绞痛症状改善明显优于对照组,治疗组治疗后血液流变学较治疗前改善,心电图总有效率分别优于对照组,差异有统计学意义(P<0.05)。结论丹红注射液是一种治疗冠心病安全、有效的药物。     

丹红注射液治疗急性脑梗死的疗效观察

目的观察丹红注射液治疗急性脑梗死的疗效。方法患者随机分为2组:治疗组(n=60)和对照组(n=55)。对照组仅用常规治疗,治疗组在常规治疗基础上加用丹红注射液治疗。结果治疗组有效率达86.7%.与对照组对比在统计学上有显著差异(P<0.01)。结论早期丹红注射液治疗急性脑梗死可明显降低血黏度,有利于脑梗死的恢复,减少复发。     

丹红注射液治疗脑梗死的疗效观察

目的观察丹红注射液治疗脑梗死的临床疗效。方法脑梗死患者96例随机分为治疗组与对照组各48例,在脑梗死常规治疗基础上,治疗组给予丹红注射液治疗,对照组给予丹参注射液治疗,两组均连续用药14d。观察2组治疗效果。结果治疗组总有效率89.6%,对照组总有效率62.5%,差异显著有统计学意义(P<0.01)。结论丹红注射液治疗脑梗死有更好的疗效,且无明显的不良反应,故临床可推广应用。     

丹红注射液治疗冠心病疗效观察

丹红注射液是从中药丹参、红花中提取液,广泛应用冠心病治疗,取得满意疗效。根据祖国医学对冠心病的认识及活血化瘀的治疗原则,以传统中医辨证施治为指导,采用现代微机技术、植物化学、分析化学、药理学等科学理论和方法提取纯中药制剂。本文通过对冠心病患者心     

A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis

ABSTRACT

Introduction: Pirfenidone is a novel oral anti-fibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). Since IPF is a chronic and progressive disease most commonly encountered in an older population, therapeutic options should be not only effective, but also free from drug interactions and as safe and tolerable as possible.

Areas covered: Comprehensive data from randomized controlled trials, meta-analyses, safety studies, and post-marketing data are available to assess the efficacy and safety of pirfenidone in the treatment of IPF. Information on efficacy, adverse events, drug tolerability and discontinuation rates both in clinical trials and real-world clinical experiences are reported.

Expert opinion: Pirfenidone has an abundance of data supporting its use in mild-to-moderate IPF. Observational evidence suggests a similar efficacy in severe IPF. In clinical trials, observational studies and real-world use, adverse events are frequent, though generally mild and well tolerated, especially with adequate patient education. Preventative strategies, along with timely and appropriate management of adverse events are critical in improving patient compliance, thereby ensuring the benefits of long-term treatment with pirfenidone.     

丹红注射液治疗不稳定型心绞痛临床疗效及安全性研究

目的分析讨论丹红注射液治疗不稳定型心绞痛的临床疗效及安全性。方法今采集2010至2011年因心绞痛来我院就诊患者112例,随机分成实验组与对照组,对照组60例,服用常规药物治疗,实验组52例,加用丹红注射液治疗,并对患者用药前后心绞痛发作次数和症状、心肌酶谱分析、心电图改善情况行对比分析。结果用药1个疗程后,实验组心绞痛症状消失7例,减轻41例,未见改善4例,总有效率92．3％;心电图恢复正常者12例,改善34例,无变化6例,总有效率88．5％;心肌酶谱恢复正常12例,降低34例,未改善6例,总改善率88．5％。对照组症状消失9例,减轻35例,未见改善者16例,总有效率73．3％;心电图恢复正常者16例,改善30例,无变化14例,总有效率76．7％;心肌酶谱恢复正常16例,降低30例,未改善14例,总改善率76．7％。实验组心绞痛发作次数、心肌酶谱和心电图改善情况明显优于对照组,差异有显著性（P〈0．05）。结论丹红注射液能缓解心绞痛症状、减少发作次数,对于不稳定型心绞痛临床疗效较常规治疗方式更优。     

阿魏酸钠治疗特发性肺纤维化的应用观察

目的探讨阿魏酸钠对特发性肺纤维化患者血清结缔组织生长因子（CTGF）、基质金属蛋白酶-9（MMP-9）、组织抑制物-1（TIMP-1）的影响。方法46例特发性肺纤维化患者随机分为对照组20例给予常规治疗;治疗组26例在常规治疗基础上加用阿魏酸钠。治疗前后检测血清CTGF、MMP-9、TIMP-1。结果治疗组治疗后CTGF、MMP-9、TIMP-1均有明显改善,与对照组比较差异有统计学意义（P〈0．05）。结论阿魏酸钠可能通过改善血清CTGF、MMP-9、TIMP-1水平而改善特发性肺纤维化患者的病情。     

Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis(IPF) is a serious and fatal pulmonary inflammatory disease with an increasing incidence worldwide. The drugs nintedanib and pirfenidone, are listed as conditionally recommended drugs in the “Evidence-Based Guidelines for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis”. However, these two drugs have many adverse reactions in clinical application. Salvianolic acid B(Sal B), a water-soluble component of Salvia miltiorrhiza, could alleviate bleomycin-induc...     

Pirfenidone for the treatment of idiopathic pulmonary fibrosis

Although multidrug therapy is required in order to achieve good blood pressure control in many hypertensives, there are no studies directly comparing fixed-dose combinations as initial therapy. The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial compares regimens of benazepril plus amlodipine versus benazepril plus hydrochlorothiazide, force-titrated to 40/10 and 40/25mg, respectively. A total of 12,600 high-risk hypertensives have been randomised and will be followed for 3 – 5years, during which cardiovascular events will be monitored. The investigators hypothesise that the benazepril plus amlodipine regimen will decrease cardiovascular events by 15% compared with benazepril plus hydrochlorothiazide. Recruitment began in 2003, and the trial is expected to end in 2008. The ACCOMPLISH trial shares important limitations with many other recent trials that will make it difficult to apply the results in clinical practice. These include the focus on high-risk hypertensive patients, in whom significant reductions in relative risk will translate into meaningful reductions in absolute risk: in lower-risk hypertensives with a low absolute risk, similar relative risk reductions may not be of great impact on the population disease burden. In ACCOMPLISH, as in most industry-sponsored clinical trials, the main goal appears to be market-driven: doses of drugs tested are not those available for clinical practice. The question asked, whether the combination of benazepril with either diuretic or dihydropyridine calcium channel blocker is more efficacious, is not a clinically compelling one. Finally, the univariate subgroup analyses proposed are unlikely to lead to an understanding of whether either combination has specific advantages for patients encountered clinically, most of whom have multiple risk factors. Thus, it appears that ACCOMPLISH, as with many recent pharmacological trials, will not greatly impact the treatment of hypertension.     

Advances in the treatment of idiopathic pulmonary fibrosis

Introduction: Idiopathic pulmonary fibrosis (IPF) is a lung limited, progressive fibrotic disease with a poor prognosis. The cause is unknown, and currently there is no treatment that reverses the disease or stops progression. This combination of a poor prognosis and the absence of curative therapy has prompted a sustained investigative effort to identify beneficial treatments. Recently released trial results suggest progress.

Areas covered: Although the mechanism of disease is poorly understood, a number of compounds that influence pathways thought to play a mechanistic role have been studied for use in IPF. This article discusses a number of these landmark trials.

Expert opinion: From these studies we conclude that the future treatment of IPF will include expanding pharmacological options. Recent studies have identified two agents that appear to slow disease progression and may offer a window into pathogenesis and future drug targets.     

泼尼松、N-乙酰半胱氨酸联合小剂量罗红霉素治疗特发性肺间质纤维化的临床疗效

目的 探讨泼尼松、N-乙酰半胱氨酸（NAC）和小剂量罗红霉素联合用药在特发性肺间质纤维化（IPF）治疗中的应用效果.方法 62例lPF患者随机分为对照组20例、联合治疗A组21例、联合治疗B组21例,在对照组给予泼尼松常规治疗,联合治疗A组在对照组基础上加用NAC,联合治疗B组在A组基础上加用小剂量罗红霉素.治疗12周后观察3组临床缓解率、肺总量（TLC）、肺活量（VC）、第1秒用力呼出量与用力肺活量比（FEV1/FVC）、一氧化碳弥散量（DLCO）和动脉血氧分压（PaO2）变化.结果 联合治疗A、B组临床缓解率分别为81.0%和85.7%,均高于对照组的45.0%,治疗后联合治疗A、B组TLC、VC、FEV1/FVC、DLCO及PaO2显著高于对照组,差异有统计学意义（P〈0.05）;而联合治疗B组各指标显著高于联合治疗A组,差异有统计学意义（P〈0.05）.结论 泼尼松、NAC和小剂量罗红霉素三药联合治疗IPF效果好.     

丹红注射液联合硝酸甘油治疗急性心肌梗死的疗效观察及相关机制研究

目的 探讨丹红注射液联合硝酸甘油治疗急性心肌梗死的疗效及相关机制.方法 100例急性心肌梗死患者随机分为对照组和研究组,每组50例.对照组给予硝酸甘油治疗,研究组在硝酸甘油基础上静脉注射丹红注射液.两组疗程均为7d.对比分析两组患者治疗总有效率,治疗前后细胞因子、MMP-9、BNP、左室功能变化情况及药物副反应.结果 研究组总有效率(90％)明显高于对照组(72％)(P＜0.05).两组治疗后血清hs-CRP和IL-10水平较治疗前明显下降(P＜0.05),研究组治疗后血清hs-CRP和IL-10水平低于对照组(P＜0.05).两组治疗后血浆MMP-9和BNP水平较治疗前明显下降(P＜0.05),研究组治疗后血浆MMP-9和BNP水平低于对照组(P＜0.05).两组患者均未发生严重药物副反应.结论 急性心肌梗死患者应用丹红注射液联合硝酸甘油治疗效果明显,其作用机制可能与降低血清hs-CRP和IL-10水平及血浆MMP-9和BNP水平相关.     

Nintedanib for the treatment of idiopathic pulmonary fibrosis

Introduction: Idiopathic Pulmonary Fibrosis (IPF) is an interstitial lung disease characterized by the progressive loss of pulmonary function, ultimately leading to respiratory failure and death. Two novel compounds, nintedanib and pirfenidone, have shown efficacy in reducing the rate of decline of lung function in IPF patients. The multiple tyrosine kinase inhibitor nintedanib has extensively being studied as a potential angiogenesis inhibitor in clinical against various neoplastic disorders. Afterwards, this compound was successfully tested in IPF.

Areas covered: Herein, the authors review the working mechanisms of nintedanib, its pharmacological profile, and its efficacy and safety for patients with IPF.

Expert opinion: Nintedanib has shown to be safe and effective in patients with IPF, with a favorable long-term safety profile. There is a lack of comparative trials of pirfenidone and nintedanib, and the choice of treatment is left to the physicians’ judgement. Future directions of nintedanib use are represented by the treatment of progressive fibrosing interstitial lung disease other than IPF, IPF with advanced functional impairment, and lung fibrosis secondary to connective tissue diseases. A promising safety profile for the combinational use of nintedanib and pirfenidone in IPF has also recently emerged.     

特发性肺纤维化27例临床分析

目的通过探讨特发性肺纤维化(IPF)的临床特点,提高对IPF的认识。方法对27例符合美国胸科协会提出的IPF诊断标准的IPF患者进行回顾性分析。结果男女之比为19∶8,年龄45～76岁,伴有咳嗽、进行性呼吸困难和Velcro罗音,X线表现为磨玻璃样、网状、结节状及蜂窝状阴影。肺功能检查示18例限制性通气功能障碍,9例混合性通气功能障碍。血气分析示低氧血症。糖皮质激素可使患者病情得到近期缓解。结论对长期咳嗽伴有进行性呼吸困难的患者,及时行胸部X线、肺功能、血气分析及经支气管肺活检,能对本病做出正确的诊断。